133081-26-2|2,5-Dioxopyrrolidin-1-yl 6-(2-(tert-butoxycarbonyl)hydrazinyl)nicotinate| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 133081-26-2 ] Purity: 95% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 133081-26-2 ]

CAS No. :	133081-26-2
Formula :	C₁₅H₁₈N₄O₆
M.W :	350.33
SMILES Code :	CC(C)(C)OC(=O)NNC1=NC=C(C=C1)C(=O)ON1C(=O)CCC1=O
MDL No. :	MFCD03788694
InChI Key :	PHWZJVJAIAVOAP-UHFFFAOYSA-N
Pubchem ID :	15343047

Safety of [ 133081-26-2 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H315-H319-H335
Precautionary Statements:	P261-P305+P351+P338

Application In Synthesis of [ 133081-26-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 133081-26-2 ]

[ 133081-26-2 ] Synthesis Path-Downstream 1~35

1
[ 133081-26-2 ]
octreotide(Boc) [ No CAS ]
C₆₅H₈₇N₁₃O₁₅S₂ [ No CAS ]

References: [1]Liebigs Annales,1996,p. 1463 - 1469.

2
[ 133081-26-2 ]
[ 182410-64-6 ]
[ 182410-65-7 ]

References: [1]Liebigs Annales,1996,p. 1463 - 1469.

3
[ 133081-26-2 ]
[(5S,11S,14R)-14-(4-Amino-butyl)-11-(3-guanidino-propyl)-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaaza-bicyclo[15.3.1]henicosa-1⁽²⁰⁾,17⁽²¹⁾,18-trien-5-yl]-acetic acid; compound with trifluoro-acetic acid [ No CAS ]
[(5S,11S,14R)-14-(4-[6-(N'-tert-Butoxycarbonyl-hydrazino)-pyridine-3-carbonyl]-amino}-butyl)-11-(3-guanidino-propyl)-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaaza-bicyclo[15.3.1]henicosa-1⁽²¹⁾,17,19-trien-5-yl]-acetic acid; compound with trifluoro-acetic acid [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,1997,vol. 7,p. 955 - 960.

4
[ 133081-26-2 ]
[(5S,11S,14R)-19-(6-Amino-hexanoylamino)-11-(3-guanidino-propyl)-14-isopropyl-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaaza-bicyclo[15.3.1]henicosa-1⁽²⁰⁾,17⁽²¹⁾,18-trien-5-yl]-acetic acid; compound with trifluoro-acetic acid [ No CAS ]
C₄₃H₆₃N₁₃O₁₁*C₂HF₃O₂ [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,1997,vol. 7,p. 955 - 960.

5
[ 6066-82-6 ]
[ 133081-25-1 ]
[ 133081-26-2 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2009,vol. 19,p. 4764 - 4767.
[2]Journal of labelled compounds and radiopharmaceuticals,1997,vol. 40,p. 455 - 457.
[3]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 3440 - 3444.
[4]RSC Advances,2015,vol. 5,p. 93374 - 93385.
[5]Journal of labelled compounds and radiopharmaceuticals,2017,vol. 60,p. 431 - 438.

6
[ 105047-45-8 ]
[ 133081-26-2 ]
Fmoc-N-ε(Hynic-Boc)-L-lysine [ No CAS ]
6-[6-[6-(N'-tert-butoxycarbonyl-hydrazino)-pyridine-3-carbonyl]-amino}-2-(9H-fluoren-9-ylmethoxycarbonylamino)-hexanoylamino]-2-(9H-fluoren-9-ylmethoxycarbonylamino)-hexanoic acid [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2003,vol. 46,p. 1751 - 1757.

7
[ 110990-08-4 ]
[ 133081-26-2 ]
C₃₂H₃₇N₅O₇ [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 1418 - 1422.

8
2',3'-dideoxy-3'-(γ-aminobutyryl)amino-thymidine [ No CAS ]
[ 133081-26-2 ]
[ 945034-56-0 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 3440 - 3444.

9
3'-(δ-aminohexanoyl)amino-3'-deoxy-thymidine [ No CAS ]
[ 133081-26-2 ]
[ 945034-57-1 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 3440 - 3444.

10
3'-[(11-amino-1-oxoundecyl)-amino]-3'-deoxythymidine [ No CAS ]
[ 133081-26-2 ]
[ 945034-58-2 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 3440 - 3444.

11
[ 143526-94-7 ]
[ 133081-26-2 ]
[ 945034-48-0 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 3440 - 3444.

12
[ 5326-23-8 ]
[ 133081-26-2 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 3440 - 3444.
[2]Journal of labelled compounds and radiopharmaceuticals,1997,vol. 40,p. 455 - 457.
[3]Letters in Organic Chemistry,2014,vol. 11,p. 208 - 214.
[4]RSC Advances,2015,vol. 5,p. 93374 - 93385.
[5]Journal of labelled compounds and radiopharmaceuticals,2017,vol. 60,p. 431 - 438.

13
[ 133081-24-0 ]
[ 133081-26-2 ]

14
[ 133081-26-2 ]
3'-(6-hydrazinopyridine-3-carbonyl)amino-3'-deoxythymidine [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 3440 - 3444.

15
[ 133081-26-2 ]
3'-[4-(6-hydrazinopyridine-3-carbonyl-amino)-1-oxobutyl]-amino}-3'-deoxythymidine [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 3440 - 3444.

16
[ 133081-26-2 ]
3'-[6-(6-hydrazinopyridine-3-carbonyl-amino)-1-oxohexyl]-amino}-3'-deoxythymidine [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 3440 - 3444.

17
[ 133081-26-2 ]
3'-[11-(6-hydrazinopyridine-3-carbonyl-amino)-1-oxoundecyl]-amino}-3'-deoxythymidine [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2007,vol. 17,p. 3440 - 3444.

18
[ 133081-26-2 ]
C₂₇H₂₉N₅O₅ [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 1418 - 1422.
[2]Journal of Medicinal Chemistry,2007,vol. 50,p. 1418 - 1422.

19
[ 133081-26-2 ]
C₂₉H₂₈F₃N₅O₆ [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2007,vol. 50,p. 1418 - 1422.

20
[ 133081-26-2 ]
((5S,11S,14R)-11-(3-Guanidino-propyl)-19-{6-[(6-hydrazino-pyridine-3-carbonyl)-amino]-hexanoylamino}-14-isopropyl-12-methyl-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaaza-bicyclo[15.3.1]henicosa-1⁽²¹⁾,17,19-trien-5-yl)-acetic acid; compound with trifluoro-acetic acid [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,1997,vol. 7,p. 955 - 960.

21
[ 133081-26-2 ]
[ 182410-67-9 ]

References: [1]Liebigs Annales,1996,p. 1463 - 1469.

22
[ 133081-26-2 ]
[ 182410-68-0 ]

References: [1]Liebigs Annales,1996,p. 1463 - 1469.

23
[ 133081-26-2 ]
C₆₁H₇₉N₁₅O₁₃S [ No CAS ]

References: [1]Liebigs Annales,1996,p. 1463 - 1469.

24
[ 134314-57-1 ]
[ 133081-26-2 ]
C₃₈H₅₈N₈O₇S [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; for 2h;	Dimethylformamide (DMF) (2 ml) and 60 mul of diisopropylethylamine is added to 186 mg of N-For-Met-Leu-Phe-diaminohexyl amide followed by 154 mg succinimidyl-6-t-BOC-hydrazinopyridine-3-carboxylic acid in 1 ml DMF. The mixture becomes yellow and the peptide dissolves within a short time. After 2 hours, ether is added to the reaction mixture and the upper layer is discarded. Water is added to the oily residue causing a solid to form. The solid is washed with 5% sodium bicarbonate, water and ethyl acetate, and the yield is determined. The t-BOC protecting group is removed by stirring the crude product with 5 ml of trifluoroacetic acid (TFA) containing 0.1 ml of p-cresol for 15 min. at 20 C. Prolonged treatment with TFA results in increased levels of a side product. The TFA is removed by rotary evaporation, and ether is added to the residue to precipitate the deprotected peptide. The product is purified by reverse phase HPLC on a 2.5×50 cm Whatman ODS-3 column is eluted with a gradient of acetonitrile in 0.1% TFA. Fractions containing the major component is combined and the solvent is removed to yield the desired product.

References: [1]Patent: US7060251,2006,B1 .Location in patent: Page/Page column 9.

25
carboxyl-polyethylene glycol-amine [ No CAS ]
[ 133081-26-2 ]
carboxy-PEG-6-BOC-hydrazinonicotinate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With phosphate buffer; In tetrahydrofuran; at 20℃; for 4h;pH 7.5;	In a 25-mL round bottomed flask, 50 mg of carboxyl-polyethylene glycol-amine (0.0147 mmole) (Shearwater) is diluted with 2.5 ml of 10 mM phosphate buffer, pH 7.5. To the resulting solution is added 15.5 mg of N-hydroxysuccinimidyl-6-BOC-hydrazinonicotinate (Solulink) in tetrahydrofuran (THF). The resulting reaction is stirred at room temperature under argon in the dark. After 4 hours, the aqueous phase is extracted with dichloromethane (DCM). The DCM phase is dried over MgSO4 and concentrated in vacuo to provide a liquid residue which is then precipitated using ether. The precipitated PEG-polymer is collected by filtration, and washed with 10 ml of cold (-20 C.) isopropyl alcohol (IPA) to provide carboxy-PEG-6-BOC-hydrazinonicotinate (CPN-Boc) which is then diluted with 1 ml of THF. To the resulting solution is added 15 mg of N,N'-dicyclohexylcarbodiimide (DCC), and 10.2 mg of N-hydroxysuccinimide (NHS) and the reaction mixture is stirred under argon for 3 hours. Dry silica gel (1 mg) is added to the solution and allowed to settle. The supernatant is separated from the solid precipitate and the solvent is then removed under vacuum to provide a residue which is resuspended in 0.5 ml of ethyl acetate, extracted with 0.5 ml of 3M HCl for 10 minutes (3 times). The organic phase is dried over MgSO4, concentrated in vacuo and extracted with ether. Cold IPA is then added to the ethereal solution to provide compound 2 as a precipitate.

References: [1]Patent: US2006/153839,2006,A1 .Location in patent: Page/Page column 29.

26
S-(2-Thio-5-nitropyridyl)-(L)-cysteine hydrochloride [ No CAS ]
[ 133081-26-2 ]
6-(BOC-Hydrazine)nicotinamido-S-(2-thio-5-nitropyridyl)-(L)-cysteine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In 1,4-dioxane; water; sodium hydrogencarbonate;	6-(BOC-Hydrazine)nicotinamido-S-(2-thio-5-nitropyridyl)-(L)-cysteine S-(2-Thio-5-nitropyridyl)-(L)-cysteine hydrochloride (220 mg, 0.70 mmol) was dissolved in saturated aqueous sodium bicarbonate (5 ml) and a solution of succinimidyl 6-(BOC-hydrazino)nicotinate (246 g, 0.70 mmol) in dioxane (5 ml) was added and the reaction mixture was stirred at room temperature for 3 hours. Water (25 ml) was added and the aqueous solution was washed with ethyl acetate to remove unreacted ester. The aqueous phase was acidified to pH 3.3 with 1N HCl then saturated with sodium chloride. The acidic aqueous solution was extracted with ethyl acetate (2*35 ml). The combined organic extracts were dried over magnesium sulphate, filtered and concentrated to give 145 mg of a yellow solid which was suspended in ether and isolated by filtration to give 35 mg of the desired product. The filtrate was concentrated and treated with ether/hexanes to yield a further 95 mg of desired product; total yield 125 mg (35%).

References: [1]Patent: US5679778,1997,A .

27
[ 133081-26-2 ]
[ 959149-84-9 ]

Yield	Reaction Conditions	Operation in experiment
		Subsequent to the automated assembly the peptide resin (13 mg, 0.01 mmole) was transferred to a Microwave vial and Boc-HYNIC-NHS ester (5mg, 0.015 mmoleJ/HOBt (2 mg, 0.015 mmole}/DIEA (8 mul, 0.0.6 mmole) in DMF (3 ml) was added. The resin mix was left standing for 15 min at RT and thereafter placed in a microwave for 2 h at 6O0C. The 20 resin was cleaved in TFA/TIS/H2O (10:0.25:0.25) for 2h then filtrated, triturated in diethylether, rotavapory evaporated and lyophilised. The crude peptide was analysed by LC-MS (20-40%B in 20 min). The analysis demonstrated the presence of two main peaks. The crude peptide mix was purified by prep HPLC (20-35% B in 40 min). One- - fraction "was collected, analysed and lyophfliseaTVield: 1 mg of white solid. HPLC purity: 25 98%. ESI-MS: Theoretical MW: 1857.2. Obtained (M+H)2+/2: 929.5.

References: [1]Patent: WO2007/138291,2007,A2 .Location in patent: Page/Page column 60.

28
[ 1160707-22-1 ]
[ 133081-26-2 ]
[ 1160707-23-2 ]

References: [1]Journal of labelled compounds and radiopharmaceuticals,2008,vol. 51,p. 357 - 367.

29
C₃₆H₄₅N₃O₁₀*H⁽¹⁺⁾ [ No CAS ]
[ 133081-26-2 ]
C₄₇H₅₈N₆O₁₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
74%	With triethylamine; In dichloromethane; at 20℃; for 1h;	EXAMPLE 15[0115] Synthesis of 2-{3-[l-carboxy-5-({6-[N'-(4-fluoro-benzylidene)-hydrazino]- pyridine- 3-carbonyl}-amino)-pentyl]-ureido}-pentanedioic acid (15).; To a solution of compound 1 (0.040 g, 0.047 mmol) in CH2Cl2 (2 mL) was added triethylamine (0.020 mL, 0.14 mmol), followed by succinimidyl 6-(N'-tert-butoxycarbonyl-hydrazino)-nicotinate (0.020 g, 0.057 mmol, Bioconjugate Chem. 1991, 2, 333-336). After stirred for 1 hour at room temperature, the solvent was evaporated. The crude material was purified by a silica column using methanol/methylene chloride (10:90) to afford 0.032 g (74%) of compound 16. 1H NMR (400 MHz, CDCl3) £8.54 (s, IH), 7.90 (m, IH), 7.17-7.23 (m, 6H), 6.90-7.05 (m, 3H), 6.79- 6.84 (m, 6H), 6.55 (d, J= 8.8 Hz, 2H), 5.79 (m, 2H), 4.94-5.07 (m, 6H), 4.38-4.45 (m, 2H), 3.74 (m, 9H), 3.26 (m, 2H), 2.33 (m, 2H), 2.07 (m, IH), 1.85 (m, IH), 1.68 (m, IH), 1.18-1.55 (m, 13H). ESI-Mass calcd for C47H59N6O13 [M + H]+ 915.4 , found 914.9.

References: [1]Patent: WO2010/14933,2010,A2 .Location in patent: Page/Page column 36.

30
[ 133081-26-2 ]
[ 147-94-4 ]
[ 1187772-87-7 ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2009,vol. 19,p. 4764 - 4767.

31
[ 1357390-42-1 ]
[ 133081-26-2 ]
[ 1357390-43-2 ]

References: [1]Chemical Biology and Drug Design,2012,vol. 79,p. 194 - 201.

32
[ 1357390-42-1 ]
[ 133081-26-2 ]
[ 1357390-44-3 ]

References: [1]Chemical Biology and Drug Design,2012,vol. 79,p. 194 - 201.

33
[ 1448302-62-2 ]
[ 133081-26-2 ]
C₃₇H₅₈N₈O₁₄ [ No CAS ]

References: [1]Journal of Medicinal Chemistry,2013,vol. 56,p. 6108 - 6121.

34
C₄₈H₆₅ClN₄O₆⁽¹⁺⁾*Cl^(1-) [ No CAS ]
[ 133081-26-2 ]
C₅₉H₇₈ClN₇O₉⁽¹⁺⁾*Cl^(1-) [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	With sodium borate; In acetonitrile; at 4℃;pH 8.5;	TheLysine conjugate 7 (51.0 mg, 0.06mmol) was then treated with Boc-HYNIC-OSu (21.0 mg, 0.06 mmol) (Solulink, San Diego, CA).) in 2 mL acetonitrile-sodium borate buffer (0.1N, pH 8.5) (50/50, v/v) and incubated at 4 C overnight,followed by concentration under reduced pressure and TFA deprotection (1 mL TFAin 2 mL anhydrous CH2Cl2

References: [1]Bioorganic and Medicinal Chemistry Letters,2013,vol. 23,p. 6350 - 6354.

35
[ 123-56-8 ]
[ 133081-25-1 ]
[ 133081-26-2 ]

Yield	Reaction Conditions	Operation in experiment
84%	With dicyclohexyl-carbodiimide; In N,N-dimethyl-formamide; at 25℃; for 17h;Inert atmosphere;	To a solution of 6-Boc-hydrazinopyridine-3-carboxylicacid 4b (0.57 g, 2.26 mmol) and N-hydrosuccinimide (0.27g, 2.26 mmol) in DMF DCC (0.47 g, 2.26 mmol) was added.The reaction mixture became cloudy after 1h. After 16h, thereaction mixture was concentrated to dryness and the residuewas purified by chromatography on silica gel with ethyl acetateas eluant to give a white solid (0.66 g, 84%). Mp =174C. IR (ATR, cm-1) 3321; 2979; 1729; 1594; 1365; 1240;1198; 1068; 974; 641. 1H NMR (DMSO) 9.46 (s, 1H), 9.20(s, 1H), 8.76 (d, 1H, J= 2.1 Hz), 8.11 (d, 1H, J= 8.1 Hz),6.67 (d, 1H, J= 9 Hz), 2.88 (s, 4H), 1.44 (s, 9H). 13C NMR(DMSO) 172.8; 170.5; 160.9; 155.4; 151.8; 110.0; 79.6;28.0; 25.5. MS (ESI+) [M+H]: 351.00. HRMS (ESI+)[M+H]+: 351.1299 observed, 351.1305 calculated forC15H19N4O6.

References: [1]Letters in Organic Chemistry,2014,vol. 11,p. 208 - 214.

Historical Records

Technical Information

• Acyl Group Substitution • Bouveault-Blanc Reduction • Buchwald-Hartwig C-N Bond and C-O Bond Formation Reactions • Catalytic Hydrogenation • Chan-Lam Coupling Reaction • Complex Metal Hydride Reductions • Ester Cleavage • Hydride Reductions • Lawesson's Reagent • Leuckart-Wallach Reaction • Mannich Reaction • Petasis Reaction • Preparation of Amines • Reactions of Amines • Reactions with Organometallic Reagents • Specialized Acylation Reagents-Carbodiimides and Related Reagents • Specialized Acylation Reagents-Ketenes • Specialized Acylation Reagents-Vilsmeier Reagent • Ugi Reaction

Related Functional Groups of
[ 133081-26-2 ]

Amides

A413922 [362522-50-7]

2,5-Dioxopyrrolidin-1-yl 6-(2-(propan-2-ylidene)hydrazinyl)nicotinate

Similarity: 0.81

A257341 [133081-25-1]

6-(2-(tert-Butoxycarbonyl)hydrazinyl)nicotinic acid

Similarity: 0.76

A381164 [23405-15-4]

2,5-Dioxopyrrolidin-1-yl benzoate

Similarity: 0.59

A527165 [199296-40-7]

tert-Butyl (5-formylpyridin-2-yl)carbamate

Similarity: 0.59

A116891 [171178-34-0]

4-((tert-Butoxycarbonyl)amino)nicotinic acid

Similarity: 0.57

Hydrazides

A257341 [133081-25-1]

6-(2-(tert-Butoxycarbonyl)hydrazinyl)nicotinic acid

Similarity: 0.76

A165551 [156899-02-4]

3-(2-(tert-Butoxycarbonyl)hydrazinyl)benzoic acid

Similarity: 0.54

A532623 [198904-85-7]

tert-Butyl 2-(4-(pyridin-2-yl)benzyl)hydrazinecarboxylate

Similarity: 0.52

Esters

A413922 [362522-50-7]

2,5-Dioxopyrrolidin-1-yl 6-(2-(propan-2-ylidene)hydrazinyl)nicotinate

Similarity: 0.81

A381164 [23405-15-4]

2,5-Dioxopyrrolidin-1-yl benzoate

Similarity: 0.59

A148711 [35657-41-1]

tert-Butyl (4-nitrobenzoyl)oxycarbamate

Similarity: 0.54

A125257 [39658-41-8]

Ethyl 6-aminonicotinate

Similarity: 0.54

A425289 [193269-82-8]

1,3-Dioxo-3a,4,7,7a-tetrahydro-1H-4,7-methanoisoindol-2(3H)-yl 4-nitrobenzyl carbonate

Similarity: 0.54

Amines

A413922 [362522-50-7]

2,5-Dioxopyrrolidin-1-yl 6-(2-(propan-2-ylidene)hydrazinyl)nicotinate

Similarity: 0.81

A257341 [133081-25-1]

6-(2-(tert-Butoxycarbonyl)hydrazinyl)nicotinic acid

Similarity: 0.76

A185062 [133081-24-0]

6-Hydrazinylnicotinic acid

Similarity: 0.60

A527165 [199296-40-7]

tert-Butyl (5-formylpyridin-2-yl)carbamate

Similarity: 0.59

A116891 [171178-34-0]

4-((tert-Butoxycarbonyl)amino)nicotinic acid

Similarity: 0.57

Hydrazines

A257341 [133081-25-1]

6-(2-(tert-Butoxycarbonyl)hydrazinyl)nicotinic acid

Similarity: 0.76

A185062 [133081-24-0]

6-Hydrazinylnicotinic acid

Similarity: 0.60

A165551 [156899-02-4]

3-(2-(tert-Butoxycarbonyl)hydrazinyl)benzoic acid

Similarity: 0.54

A532623 [198904-85-7]

tert-Butyl 2-(4-(pyridin-2-yl)benzyl)hydrazinecarboxylate

Similarity: 0.52

Related Parent Nucleus of
[ 133081-26-2 ]

Pyrrolidines

A413922 [362522-50-7]

2,5-Dioxopyrrolidin-1-yl 6-(2-(propan-2-ylidene)hydrazinyl)nicotinate

Similarity: 0.81

A381164 [23405-15-4]

2,5-Dioxopyrrolidin-1-yl benzoate

Similarity: 0.59

A107972 [38862-24-7]

2,5-Dioxopyrrolidin-1-yl acrylate

Similarity: 0.50

Pyridines

A413922 [362522-50-7]

2,5-Dioxopyrrolidin-1-yl 6-(2-(propan-2-ylidene)hydrazinyl)nicotinate

Similarity: 0.81

A257341 [133081-25-1]

6-(2-(tert-Butoxycarbonyl)hydrazinyl)nicotinic acid

Similarity: 0.76

A185062 [133081-24-0]

6-Hydrazinylnicotinic acid

Similarity: 0.60

A527165 [199296-40-7]

tert-Butyl (5-formylpyridin-2-yl)carbamate

Similarity: 0.59

A116891 [171178-34-0]

4-((tert-Butoxycarbonyl)amino)nicotinic acid

Similarity: 0.57

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

{[proInfo.proName]}

CAS No.: 133081-26-2

{[proInfo.proName]}

CAS No.: 133081-26-2

Alternative Products

Product Details of [ 133081-26-2 ]

Safety of [ 133081-26-2 ]

Application In Synthesis of [ 133081-26-2 ]

[ 133081-26-2 ] Synthesis Path-Downstream 1~35

Related Products

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 133081-26-2 ]

Amides

Hydrazides

Esters

Amines

Hydrazines

Related Parent Nucleus of
[ 133081-26-2 ]

Pyrrolidines

Pyridines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

{[proInfo.proName]}

CAS No.: 133081-26-2

{[proInfo.proName]}

CAS No.: 133081-26-2

Alternative Products

Product Details of [ 133081-26-2 ]

Safety of [ 133081-26-2 ]

Application In Synthesis of [ 133081-26-2 ]

[ 133081-26-2 ] Synthesis Path-Downstream 1~35

Related Products

Historical Records

Technical Information

Categories

Related Functional Groups of [ 133081-26-2 ]

Amides

Hydrazides

Esters

Amines

Hydrazines

Related Parent Nucleus of [ 133081-26-2 ]

Pyrrolidines

Pyridines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Related Functional Groups of
[ 133081-26-2 ]

Related Parent Nucleus of
[ 133081-26-2 ]